« Back

International Progressive MS Alliance


Wednesday October 14 2015 03:13 PM

UPDATED Public Statement – Positive Results Reported from Genentech/Roche Phase III Trial of Ocrelizumab in Primary Progressive MS

10 October, 2015

There are currently no approved disease-modifying therapies to treat progressive MS, but results from a recent Phase III trial may start shifting that landscape.  In a late September press announcement by Genentech, a member of the Roche Group, the company announced that the experimental monoclonal antibody, ocrelizumab, significantly slowed progression of disability compared to placebo in a Phase III ORATORIO trial involving 732 people with primary progressive MS.  

Additional data from the trial reported 10 October at the European Committee for Treatment and Research in MS (ECTRIMS) in Barcelona showed that, compared to placebo, ocrelizumab significantly reduced the risk of progression of clinical disability by 24% compared with placebo, and over 120 weeks it also reduced the time required to walk 25 feet by 29%, decreased the volume of brain lesions by 3.4%, and reduced the rate of whole brain volume loss by 17.5%. While this impact against progression was modest, this is the first large-scale clinical trial to show positive results in people with primary progressive MS.   

“The results of the ocrelizumab trial in people with primary progressive MS are an encouraging development in the search for effective treatments for this disabling form of MS,” said Professor Alan Thompson, Chair of the International Progressive MS Alliance Scientific Steering Committee. “While the reported effects on progression are modest, the data clearly indicate that this treatment has potential benefit and is not only a source of hope, but also an important milestone that will further inform development for effective treatments for everyone with progressive forms of MS.”

The Alliance will continue to monitor all potential area of progress and increased understanding in order to accelerate the development of treatment for people with progressive MS.

Further reading

About Progressive MS

About the Alliance

Author: International Progressive MS Alliance

Tags: primaryprogressivems, internationalprogressivemsalliance



Tuesday March 08 2016 15:51

Very excited to hear about this. Have you any idea when it might be available to trial in Ireland?

Add a comment

Your email address will not be published and will only be used by MS Ireland to contact you should there be an issue with your comment.

Please read our policy on making comments. Basically, respect other people’s view, use appropriate language and be nice! Comments are published between 9am and 5pm, Monday to Friday.

We ask this question to ensure that you are a real person, and not a computer adding information automatically.

By commenting, you are adhering to our Terms of use / Privacy

Latest News

More news

What's hot


Women's Mini Marathon

Join our MS Squad for the Vhi Women's Mini Marathon on June 2nd and help us raise essential funds for our support services across Ireland. Sign up early to make sure you’re in!

Find out more

Events Calendar

» Our next Event

20 April 2019: Physio led exercise classes for people with MS, starts 12th January (ongoing) please contact Una Goan.

View all events


If you'd like to receive e-news updates from The Society please enter your email address below. If you want to know more about how we manage personal data then please see our privacy policy.

My local MSI

Map of MS Ireland's service areas South Mid West West Midlands South East North East North West North Dublin City and Fingal South West Dublin and Kildare South East Dublin and Wicklow